Compare iShares MSCI South Korea ETF (EWY) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares MSCI South Korea ETF vs Johnson & Johnson — how do they compare? iShares MSCI South Korea ETF trades at $176.88 (market cap $26.25B), while Johnson & Johnson trades at $261.3 (market cap $618.09B). The key difference: Johnson & Johnson is far larger — about 23.5× iShares MSCI South Korea ETF's market cap, and Johnson & Johnson pays a 2.09% dividend while iShares MSCI South Korea ETF pays none. Which is the better fit depends on your goals — on Pluang, investors hold iShares MSCI South Korea ETF for 46 Days and Johnson & Johnson for 129 Days on average.
| EWY | JNJ | |
|---|---|---|
Market Cap | $26.25B | $618.09B |
Volume | 19,056,075 | 6,050,983 |
Sector | Broad Market / Factor | Health |
52-Week High | $219.20 | $278.43 |
52-Week Low | $80.72 | $186.00 |
Typical Hold Time | 46 Days | 129 Days |
Enterprise Value | — | $646.37B |
Dividend Yield | — | 2.09% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
EWY (iShares MSCI South Korea ETF) is trading at $176.77, down 3.78% amid broader Asian market pressures. The ETF shows a bearish technical signal with moving averages indicating selling pressure, though oversold RSI levels suggest potential near-term support. Recent volatility reflects sensitivity to semiconductor cycles, with heavy concentration in Samsung and SK hynix driving performance. South Korea's KOSPI has struggled to maintain gains above 7,000 despite AI-driven optimism, facing headwinds from rising oil prices and global bond yields.
The outlook remains tied to semiconductor demand and AI infrastructure spending, with corporate earnings showing resilience. Key risks include concentration in two holdings, memory cycle dependency, and macroeconomic pressures. Governance reforms and visible deleveraging provide fundamental support, but the ETF's high sensitivity to tech sector volatility warrants caution for risk-averse investors.
Johnson & Johnson (JNJ) trades at $259.62, up 0.45% with a bearish technical signal despite recent earnings beats. The stock shows strong fundamentals with 21.48% net margin and 25.74% ROE, though valuation ratios appear elevated with P/E at 29.75. Recent news highlights growth in the Innovative Medicine segment and positive analyst coverage with 52.5% buy ratings.
JNJ offers stable dividend income and pharmaceutical innovation upside, but faces patent cliff risks and increasing debt-to-asset ratio (24.06% in 2025). Analyst consensus target of $286.53 suggests 10% upside potential, though technical resistance at $260 may limit near-term gains.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares MSCI South Korea ETF
EWY tracks the MSCI Korea 25/50 Index, offering targeted exposure to large and mid-cap companies in South Korea. It is structurally centered on the global technology supply chain, industrials, and financial services, serving as a liquid tool for investors seeking a single-country view of this advanced, innovation-led economy.
Read more on EWY →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
